Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05678010 · ClinicalTrials.gov registry record · Phase 1
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
A Phase 1 study of Solid Tumor and Metastatic Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 5
- Study locations
NCT05678010: Active Phase 1 study of Solid Tumor and Metastatic Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05678010 is a Phase 1 study of Solid Tumor and Metastatic Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 54 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (76% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05678010, a Phase 1 study of Solid Tumor and Metastatic Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to find out whether AZD1390 combined with stereotactic body radiation therapy/SBRT is a safe treatment for people with metastatic solid tumor cancer
Primary Outcome
The primary objective is to assess the safety and tolerability of concurrent AZD1390 with SBRT for patients with solid tumor metastases with solid tumor metastases. Participant toxicities will be assessed using the CTCAE v5.0
Conditions Studied
Interventions
- RADIATION Stereotactic Body Radiotherapy
- DRUG AZD1390
Study Locations (5)
New York
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
Washington
- University of Washington (Data Collection AND Data Analysis) - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2023-05-17 |
| Est. Completion | 2028-05-17 |
| Phase | Phase 1 |
What the registry record for NCT05678010 still lists
NCT05678010 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (76% lower).
The record links to 6 conditions, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Stereotactic Body Radiotherapy is the first listed.
NCT05678010 lists 5 locations in 3 states (New York, New Jersey, Washington).
Frequently Asked Questions
What is clinical trial NCT05678010 about?
NCT05678010 is a clinical study titled "A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer". The purpose of this study is to find out whether AZD1390 combined with stereotactic body radiation therapy/SBRT is a safe treatment for people with metastatic solid tumor cancer
What is the current status of trial NCT05678010?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2023-05-17. Estimated completion is 2028-05-17.
What conditions does trial NCT05678010 study?
This clinical trial studies the following conditions: Solid Tumor, Metastatic Cancer, Solid Tumor, Adult, Metastatic Solid Tumor, Solid Carcinoma.
What interventions are being tested in trial NCT05678010?
The interventions under investigation include: Stereotactic Body Radiotherapy (RADIATION), AZD1390 (DRUG).
Who is sponsoring clinical trial NCT05678010?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05678010 being conducted?
This trial has 5 study locations across New Jersey, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05678010's enrollment target sits among peer trials
54 117th of 196 higher than 78 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI